NeuroSigma

NeuroSigma, Inc. is a California-based life sciences company dedicated to developing bioelectronic technologies with the potential to transform medical practice and improve patients' lives. NeuroSigma focuses on TNS neuromodulation therapy based on intellectual property, exclusively licensed from the University of California, Los Angeles (UCLA), covering a range of conditions including ADHD, epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as pioneering Phase I, II, and III clinical trials.